Statin Use and COVID-19 Infectivity and Severity in South Korea: Two Population-Based Nationwide Cohort Studies
BackgroundBasic studies suggest that statins as add-on therapy may benefit patients with COVID-19; however, real-world evidence of such a beneficial association is lacking. ObjectiveWe investigated differences in SARS-CoV-2 test positivity and clinical outcomes of...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2021-10-01
|
| Series: | JMIR Public Health and Surveillance |
| Online Access: | https://publichealth.jmir.org/2021/10/e29379 |
| _version_ | 1797735707143307264 |
|---|---|
| author | Seung Won Lee So Young Kim Sung Yong Moon In Kyung Yoo Eun-Gyong Yoo Gwang Hyeon Eom Jae-Min Kim Jae Il Shin Myung Ho Jeong Jee Myung Yang Dong Keon Yon |
| author_facet | Seung Won Lee So Young Kim Sung Yong Moon In Kyung Yoo Eun-Gyong Yoo Gwang Hyeon Eom Jae-Min Kim Jae Il Shin Myung Ho Jeong Jee Myung Yang Dong Keon Yon |
| author_sort | Seung Won Lee |
| collection | DOAJ |
| description |
BackgroundBasic studies suggest that statins as add-on therapy may benefit patients with COVID-19; however, real-world evidence of such a beneficial association is lacking.
ObjectiveWe investigated differences in SARS-CoV-2 test positivity and clinical outcomes of COVID-19 (composite endpoint: admission to intensive care unit, invasive ventilation, or death) between statin users and nonusers.
MethodsTwo independent population-based cohorts were analyzed, and we investigated the differences in SARS-CoV-2 test positivity and severe clinical outcomes of COVID-19, such as admission to the intensive care unit, invasive ventilation, or death, between statin users and nonusers. One group comprised an unmatched cohort of 214,207 patients who underwent SARS-CoV-2 testing from the Global Research Collaboration Project (GRCP)-COVID cohort, and the other group comprised an unmatched cohort of 74,866 patients who underwent SARS-CoV-2 testing from the National Health Insurance Service (NHIS)-COVID cohort.
ResultsThe GRCP-COVID cohort with propensity score matching had 29,701 statin users and 29,701 matched nonusers. The SARS-CoV-2 test positivity rate was not associated with statin use (statin users, 2.82% [837/29,701]; nonusers, 2.65% [787/29,701]; adjusted relative risk [aRR] 0.97; 95% CI 0.88-1.07). Among patients with confirmed COVID-19 in the GRCP-COVID cohort, 804 were statin users and 1573 were matched nonusers. Statin users were associated with a decreased likelihood of severe clinical outcomes (statin users, 3.98% [32/804]; nonusers, 5.40% [85/1573]; aRR 0.62; 95% CI 0.41-0.91) and length of hospital stay (statin users, 23.8 days; nonusers, 26.3 days; adjusted mean difference –2.87; 95% CI –5.68 to –0.93) than nonusers. The results of the NHIS-COVID cohort were similar to the primary results of the GRCP-COVID cohort.
ConclusionsOur findings indicate that prior statin use is related to a decreased risk of worsening clinical outcomes of COVID-19 and length of hospital stay but not to that of SARS-CoV-2 infection. |
| first_indexed | 2024-03-12T13:02:44Z |
| format | Article |
| id | doaj.art-f912d00facec4865a2237031e164f5d6 |
| institution | Directory Open Access Journal |
| issn | 2369-2960 |
| language | English |
| last_indexed | 2024-03-12T13:02:44Z |
| publishDate | 2021-10-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | JMIR Public Health and Surveillance |
| spelling | doaj.art-f912d00facec4865a2237031e164f5d62023-08-28T19:30:02ZengJMIR PublicationsJMIR Public Health and Surveillance2369-29602021-10-01710e2937910.2196/29379Statin Use and COVID-19 Infectivity and Severity in South Korea: Two Population-Based Nationwide Cohort StudiesSeung Won Leehttps://orcid.org/0000-0001-5632-5208So Young Kimhttps://orcid.org/0000-0002-7361-4930Sung Yong Moonhttps://orcid.org/0000-0002-8982-9477In Kyung Yoohttps://orcid.org/0000-0003-0909-339XEun-Gyong Yoohttps://orcid.org/0000-0002-6452-655XGwang Hyeon Eomhttps://orcid.org/0000-0002-7904-8503Jae-Min Kimhttps://orcid.org/0000-0001-7409-6306Jae Il Shinhttps://orcid.org/0000-0003-2326-1820Myung Ho Jeonghttps://orcid.org/0000-0003-2424-810XJee Myung Yanghttps://orcid.org/0000-0001-5729-2233Dong Keon Yonhttps://orcid.org/0000-0003-1628-9948 BackgroundBasic studies suggest that statins as add-on therapy may benefit patients with COVID-19; however, real-world evidence of such a beneficial association is lacking. ObjectiveWe investigated differences in SARS-CoV-2 test positivity and clinical outcomes of COVID-19 (composite endpoint: admission to intensive care unit, invasive ventilation, or death) between statin users and nonusers. MethodsTwo independent population-based cohorts were analyzed, and we investigated the differences in SARS-CoV-2 test positivity and severe clinical outcomes of COVID-19, such as admission to the intensive care unit, invasive ventilation, or death, between statin users and nonusers. One group comprised an unmatched cohort of 214,207 patients who underwent SARS-CoV-2 testing from the Global Research Collaboration Project (GRCP)-COVID cohort, and the other group comprised an unmatched cohort of 74,866 patients who underwent SARS-CoV-2 testing from the National Health Insurance Service (NHIS)-COVID cohort. ResultsThe GRCP-COVID cohort with propensity score matching had 29,701 statin users and 29,701 matched nonusers. The SARS-CoV-2 test positivity rate was not associated with statin use (statin users, 2.82% [837/29,701]; nonusers, 2.65% [787/29,701]; adjusted relative risk [aRR] 0.97; 95% CI 0.88-1.07). Among patients with confirmed COVID-19 in the GRCP-COVID cohort, 804 were statin users and 1573 were matched nonusers. Statin users were associated with a decreased likelihood of severe clinical outcomes (statin users, 3.98% [32/804]; nonusers, 5.40% [85/1573]; aRR 0.62; 95% CI 0.41-0.91) and length of hospital stay (statin users, 23.8 days; nonusers, 26.3 days; adjusted mean difference –2.87; 95% CI –5.68 to –0.93) than nonusers. The results of the NHIS-COVID cohort were similar to the primary results of the GRCP-COVID cohort. ConclusionsOur findings indicate that prior statin use is related to a decreased risk of worsening clinical outcomes of COVID-19 and length of hospital stay but not to that of SARS-CoV-2 infection.https://publichealth.jmir.org/2021/10/e29379 |
| spellingShingle | Seung Won Lee So Young Kim Sung Yong Moon In Kyung Yoo Eun-Gyong Yoo Gwang Hyeon Eom Jae-Min Kim Jae Il Shin Myung Ho Jeong Jee Myung Yang Dong Keon Yon Statin Use and COVID-19 Infectivity and Severity in South Korea: Two Population-Based Nationwide Cohort Studies JMIR Public Health and Surveillance |
| title | Statin Use and COVID-19 Infectivity and Severity in South Korea: Two Population-Based Nationwide Cohort Studies |
| title_full | Statin Use and COVID-19 Infectivity and Severity in South Korea: Two Population-Based Nationwide Cohort Studies |
| title_fullStr | Statin Use and COVID-19 Infectivity and Severity in South Korea: Two Population-Based Nationwide Cohort Studies |
| title_full_unstemmed | Statin Use and COVID-19 Infectivity and Severity in South Korea: Two Population-Based Nationwide Cohort Studies |
| title_short | Statin Use and COVID-19 Infectivity and Severity in South Korea: Two Population-Based Nationwide Cohort Studies |
| title_sort | statin use and covid 19 infectivity and severity in south korea two population based nationwide cohort studies |
| url | https://publichealth.jmir.org/2021/10/e29379 |
| work_keys_str_mv | AT seungwonlee statinuseandcovid19infectivityandseverityinsouthkoreatwopopulationbasednationwidecohortstudies AT soyoungkim statinuseandcovid19infectivityandseverityinsouthkoreatwopopulationbasednationwidecohortstudies AT sungyongmoon statinuseandcovid19infectivityandseverityinsouthkoreatwopopulationbasednationwidecohortstudies AT inkyungyoo statinuseandcovid19infectivityandseverityinsouthkoreatwopopulationbasednationwidecohortstudies AT eungyongyoo statinuseandcovid19infectivityandseverityinsouthkoreatwopopulationbasednationwidecohortstudies AT gwanghyeoneom statinuseandcovid19infectivityandseverityinsouthkoreatwopopulationbasednationwidecohortstudies AT jaeminkim statinuseandcovid19infectivityandseverityinsouthkoreatwopopulationbasednationwidecohortstudies AT jaeilshin statinuseandcovid19infectivityandseverityinsouthkoreatwopopulationbasednationwidecohortstudies AT myunghojeong statinuseandcovid19infectivityandseverityinsouthkoreatwopopulationbasednationwidecohortstudies AT jeemyungyang statinuseandcovid19infectivityandseverityinsouthkoreatwopopulationbasednationwidecohortstudies AT dongkeonyon statinuseandcovid19infectivityandseverityinsouthkoreatwopopulationbasednationwidecohortstudies |